1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,700 | 15,100 | 06.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress | 2 | Investing.com | ||
| Mo | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Spyre Therapeutics GAAP EPS of -$0.60 | 1 | Seeking Alpha | ||
| 08.05. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 74 | PR Newswire | On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts... ► Artikel lesen | |
| 08.05. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.05. | Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 | 1 | RTTNews | ||
| 28.03. | BTIG maintains Spyre stock Buy rating, $70 target | 15 | Investing.com | ||
| 27.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody | 143 | PR Newswire | Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... ► Artikel lesen | |
| 18.03. | Wolfe Research initiates Spyre stock with Outperform rating | 3 | Investing.com | ||
| 27.02. | Spyre Therapeutics GAAP EPS of -$0.81 beats by $0.21 | 2 | Seeking Alpha | ||
| 27.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 396 | PR Newswire | Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million... ► Artikel lesen | |
| 27.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts | 175 | PR Newswire | Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025
Phase 1 interim results expected for SPY003, an extended... ► Artikel lesen | |
| 13.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies | 276 | PR Newswire | Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies
Preclinical data for both SPY002 molecules demonstrate picomolar potency and... ► Artikel lesen | |
| 12.11.24 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory ... | 152 | PR Newswire | SPY001 was well tolerated with a favorable safety profile consistent with the anti-a4ß7 class
SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase... ► Artikel lesen | |
| 07.11.24 | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 71 | PR Newswire | Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation... ► Artikel lesen | |
| 14.10.24 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations | 119 | PR Newswire | SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025
New data on SPY003 presented at UEGW demonstrating robust preclinical... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 10,300 | -7,21 % | Oruka Therapeutics, Inc. - 8-K, Current Report | ||
| PALVELLA THERAPEUTICS | 21,000 | -2,78 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 17,000 | +2,41 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results | Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103... ► Artikel lesen | |
| JOUNCE THERAPEUTICS | - | - | IBM's Red Hat acquires stealth Israeli startup Jounce for $20M to bolster AI cloud stack | ||
| LENZ THERAPEUTICS | 31,980 | +5,54 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| TOURMALINE BIO | 19,270 | +2,01 % | Tourmaline Bio, Inc. - 8-K, Current Report | ||
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,200 (+1,41 %) liegt der Kurs bei 14,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.